<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01860794</url>
  </required_header>
  <id_info>
    <org_study_id>PBC09-074</org_study_id>
    <nct_id>NCT01860794</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease</brief_title>
  <official_title>Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bundang CHA Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bundang CHA Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic
      Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is phase I/II clinical trials which is accessible to those involved in the study
      and conducted by only Bundang CHA hospital.

      The progress of the clinical trails is reported to and evaluated by Data monitoring committee
      before the enrolment of next human subject.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of cancer foramtion and infection</measure>
    <time_frame>5 years</time_frame>
    <description>If not included in the following criteria, the cells are are considered to be safe and tolerable.
Cells with grade 3 or more in NCI grading system
Cells contaminated with infectious materials
Cells with risk of cancer formation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>5 years</time_frame>
    <description>UPDRS, most commonly used, is designed to assess the severity of parkinson's disease, making the quantitative measurement of the extent. Part III of UPDRS corresponds to motor evaluation and is the most reliable for detecting symptomatic progression.
UPDRS improvement ratio(%) = ((the value of UPDRS before surgery - the value of UPDRS after surgery) / (the value of UPDRS before surgery)) X 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of positron emission in Putamen using Positron emission tomograph(PET)</measure>
    <time_frame>5 years</time_frame>
    <description>In pet analysis, putamen activity is investigated via radioactivity before cell transplantation and 12,24,36,48,60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyskinesia scale scores(CAPSIT-PD)</measure>
    <time_frame>5 years</time_frame>
    <description>Overall inspection was carried out before transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60 months after the treatment for determining whether the cells have therapeutic effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test</measure>
    <time_frame>5 years</time_frame>
    <description>Comprehensive clinical assessment for examining the improvements in self reporting and timed testing before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment:Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of activity of daily living (ADL) scale</measure>
    <time_frame>5 years</time_frame>
    <description>Comprehensive clinical assessment for examining the improvements in activity of daily living before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of Korean mini-mental examination (K-MMSE)</measure>
    <time_frame>5 years</time_frame>
    <description>Comprehensive clinical assessment for examining the improvements in mental state before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor fluctuation scale scores</measure>
    <time_frame>5 years</time_frame>
    <description>Comprehensive clinical assessment for identifying the presence of motor fluctuation symptoms before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score with patient questionnaire</measure>
    <time_frame>5 years</time_frame>
    <description>Measure of patient satisfaction before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dopaminergic drug dose</measure>
    <time_frame>5 years</time_frame>
    <description>Measure of dopaminergic drug dose before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tremor, postural instability, motor dysfunction, gait disturbance</measure>
    <time_frame>5 years</time_frame>
    <description>Using video recording, assessment for symptoms such as tremor, postural instability, motor dysfunction and gait disturbance before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing the extent of recovery with patient's diary</measure>
    <time_frame>5 years</time_frame>
    <description>Assessing the extent of recovery based on patient's diary before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Idiopathic Parkinson Disease</condition>
  <condition>Primary Parkinsonism</condition>
  <arm_group>
    <arm_group_label>Mesencephalic Neuronal Precursor Cells</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mesencephalic Neuronal Precursor Cells</intervention_name>
    <description>All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.</description>
    <arm_group_label>Mesencephalic Neuronal Precursor Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients with idiopathic or primary Parkinson's disease

          2. Hoehn and Yare (HY) stage III or IV

          3. more than 33% improvement Part III UPDRS score after one injection of levodopa in the
             morning

          4. Patients aged less than 70

          5. Great decrease of dopamine uptake in putamen, particularly posterior part, in Positron
             emission tomograph(PET) before surgery

        Exclusion Criteria:

          1. Atypical or secondary parkinsonism

          2. Medical history of severe depression with Beck Depression Inventory(BDI) scores
             greater than 30

          3. Psychological disorders (illusion, delusion, schizophrenia)

          4. Dementia with K-MMSE(Korean mini-mental state examination) scores less than 24

          5. Epilepsy

          6. Medial history of brain surgery

          7. Medical history of other brain diseases

          8. Hemorrhagic tendency

          9. Severe internal diseases such as poor general condition, hypertension, chronic
             respiratory disease, ischemic heart disease, cancer

         10. Experience of participating in clinical trial within 30 days

         11. Female patients who have the chances of getting pregnant during clinical trial and do
             not use the approved birth controls

         12. Pregnant or lactating women

         13. Patients who are not considered to be eligible to participate in clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Sup Chung, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHA University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sang Sup Chung, M.D., Ph.D.</last_name>
    <phone>82-31-780-5261</phone>
    <email>jmoon@cha.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joo pyung Kim, M.D., Ph.D.</last_name>
    <phone>82-31-780-5000</phone>
    <email>jpkim@cha.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHA Bundang Medical Center, CHA University</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-712</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sang Sup Chung, M.D., Ph.D.</last_name>
      <phone>82-31-780-5261</phone>
      <email>sschung@cha.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>In Bo Han, M.D., Ph.D.</last_name>
      <phone>82-31-780-5688</phone>
      <email>hanib@cha.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sang Sup Chung, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>In Bo Han, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joo Pyung Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yong Soo Choi, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun Sook Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Won Chan Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Heum Kim, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eun Hye Yoo, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Su Jin Jang, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jisook Moon, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <last_update_submitted>October 16, 2017</last_update_submitted>
  <last_update_submitted_qc>October 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bundang CHA Hospital</investigator_affiliation>
    <investigator_full_name>Sang Sup Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

